Q-Gen Partnership Crucial for Clinical Trial Supply
SYDNEY — NeuroScientific Biopharmaceuticals (ASX:NSB) has started scaling up the manufacturing process for its StemSmart technology, a significant step towards a Phase 2 clinical trial for Crohn’s disease. The company has initiated its first technology transfer manufacturing run at Q-Gen Cell Therapeutics in Brisbane, ensuring a robust supply chain for upcoming trials, according to a company statement released this week.
The collaboration with Q-Gen Cell Therapeutics, one of Australia’s leading cell therapy manufacturers, marks a crucial phase in the development of StemSmart, as noted by NSB’s CEO Nathan Smith. He emphasised the importance of high-quality product supply that meets global standards and highlighted successful outcomes from their Special Access Programme for Crohn’s disease.
Manufacturing Scale-Up and Clinical Trial Preparation
The technology transfer involves a comprehensive programme of six stages, including engineering and demonstration runs that are vital for regulatory approval. Dr. Marian Sturm, NSB’s Chief Scientific Officer, expressed confidence in Q-Gen’s capability to integrate the manufacturing technology into their systems. The full completion of this programme is targeted for later in 2026, which will allow NeuroScientific to proceed with clinical-scale production.
Crohn’s disease, a growing therapeutic market projected to reach US$13.8 billion by 2026, presents challenges due to its complex nature and the limitations of current treatments. StemSmart aims to offer a new therapeutic approach by modulating immune responses and reducing inflammation. The technology holds potential beyond Crohn’s disease, addressing other inflammatory conditions. This advancement signifies a promising future for patients suffering from immune disorders, as it opens avenues for more effective therapies with fewer side effects. NeuroScientific’s strategy also includes exploring partnerships and collaborations to expand the application of StemSmart to other diseases, such as multiple sclerosis and rheumatoid arthritis. These efforts underscore the company’s commitment to innovation and improving patient outcomes globally.
Source: newshub.medianet.com.au
Last updated: 4 April 2026, 6:40 pm
